XTL Biopharmaceuticals Ltd

XTAE:XTLB (Israel)  
₪ 0.09 (+2.22%) Apr 21
At Loss
P/B:
5.41
Market Cap:
₪ 50.13M ($ 13.27M)
Enterprise V:
₪ 41.84M ($ 11.07M)
Volume:
2.72M
Avg Vol (2M):
11.56M
Also Trade In:
Volume:
2.72M
At Loss

Business Description

Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.94
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year FCF Growth Rate 5
3-Year Book Growth Rate -16.4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 38.45
9-Day RSI 48.32
14-Day RSI 53.97
6-1 Month Momentum % 120.59
12-1 Month Momentum % 66.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.1
Quick Ratio 14.1
Cash Ratio 13.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2

Profitability Rank

Name Current Vs Industry Vs History
ROE % -65.89
ROA % -62.56
ROIC % -207.9
ROC (Joel Greenblatt) % -3490.81
ROCE % -50.3
Years of Profitability over Past 10-Year 2

Financials

XTAE:XTLB's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

XTL Biopharmaceuticals Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪)
EPS (TTM) (₪) -0.015
Beta 0
Volatility % 207.09
14-Day RSI 53.97
14-Day ATR (₪) 0.011101
20-Day SMA (₪) 0.10225
12-1 Month Momentum % 66.67
52-Week Range (₪) 0.03 - 0.171
Shares Outstanding (Mil) 544.91

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

XTL Biopharmaceuticals Ltd Filings

Filing Date Document Date Form
No Filing Data

XTL Biopharmaceuticals Ltd Stock Events

Financials Calendars
Event Date Price(₪)
No Event Data

XTL Biopharmaceuticals Ltd Frequently Asked Questions

What is XTL Biopharmaceuticals Ltd(XTAE:XTLB)'s stock price today?
The current price of XTAE:XTLB is ₪0.09. The 52 week high of XTAE:XTLB is ₪0.17 and 52 week low is ₪0.03.
When is next earnings date of XTL Biopharmaceuticals Ltd(XTAE:XTLB)?
The next earnings date of XTL Biopharmaceuticals Ltd(XTAE:XTLB) is .
Does XTL Biopharmaceuticals Ltd(XTAE:XTLB) pay dividends? If so, how much?
XTL Biopharmaceuticals Ltd(XTAE:XTLB) does not pay dividend.

Press Release

Subject Date
No Press Release